Navigation Links
Isis Pharmaceuticals to Present a General Corporate Update at Its 2010 Annual Meeting of Stockholders and Open House
Date:5/26/2010

xn-person">Joseph Witztum and moderated by Dr. Bruce Turner, healthcare fund manager at Bank of America.  Questions for the panelists may be submitted through Isis' Company Web site, www.isispharm.com, in advance of the meeting.

A live audio webcast of the presentations will be available on the "Investors & Media" section of the Company's Web site, www.isispharm.com.  A replay of the presentations will be available on the Isis Web site within 48 hours and will be archived for a limited time.

ABOUT ISIS PHARMACEUTICALS, INC.

Isis is exploiting its expertise in RNA to discover and develop novel drugs for its product pipeline and for its partners.  The Company has successfully commercialized the world's first antisense drug and has 22 drugs in development.  Isis' drug development programs are focused on treating cardiovascular, metabolic, and severe neurodegenerative diseases and cancer.  Isis' partners are developing antisense drugs invented by Isis to treat a wide variety of diseases.  Isis and Alnylam Pharmaceuticals are joint owners of Regulus Therapeutics Inc., a company focused on the discovery, development and commercialization of microRNA therapeutics.  Isis also has made significant innovations beyond human therapeutics resulting in products that other companies, including Abbott, are commercializing.  As an innovator in RNA-based drug discovery and devel
'/>"/>

SOURCE Isis Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Alzheimers Drug Discovery Foundation Funds American Life Science Pharmaceuticals, Inc to Move Novel Therapeutic Towards Clinic
2. China Yongxin Pharmaceuticals Reports First Quarter 2010 Financial Results
3. Epix Pharmaceuticals, Inc. Announces a Change in the May 28, 2010 Auction Sale of Epix Imaging Agents to June 22, 2010
4. Bayer HealthCare Pharmaceuticals, Inc. Announces Results of a Phase 3 Clinical Trial of Gadobutrol
5. Isis Pharmaceuticals to Present at the 2010 Citi Investment Research Global Health Care Conference
6. Onyx Pharmaceuticals Announces Carfilzomib Data Presentations at 46th American Society of Clinical Oncology Annual Meeting
7. Cumberland Pharmaceuticals to Present at Jefferies Global Life Sciences Conference in New York on June 8, 2010
8. Renhuang Pharmaceuticals Exhibits All-Natural Products at the 107th China Import and Export Fair
9. WellPoint Is First Health Benefits Company to Release CER Guidelines for Use in Evaluating Pharmaceuticals
10. Epix Pharmaceuticals, Inc. Announces Additional Information Concerning the May 28, 2010 Auction Sale of EP-3600 MRI Imaging Agent
11. Isis Pharmaceuticals to Discuss Its Cancer Franchise in a Conference Call on Wednesday, May 19
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)... 28, 2015 Perrigo Company plc ("Perrigo") (NYSE: ... N.V. ("Mylan") (NASDAQ: MYL ) shareholder vote regarding ... "Our views of Mylan,s offer to Perrigo shareholders have ... our Board,s careful reflection of the value available to ... choices that Mylan has allowed its shareholders to consider," ...
(Date:8/28/2015)... and PITTSBURGH , ... MYL ) today announced that its shareholders have ... (NYSE: PRGO ; TASE) and the related ... at an extraordinary general meeting of shareholders held ... votes cast at the extraordinary general meeting. In ...
(Date:8/28/2015)... y LONDRES, 28 de agosto de 2015 ... anunció hoy su participación en el  Congreso de ... soluciones cardiológicas más recientes y novedosas, entre ellas ... conectan a las personas y la tecnología con ... a diagnosticar, guiar los tratamientos y permitir atención ...
Breaking Medicine Technology:Perrigo Confident Its Shareholders Will Reject Mylan's Value Destructive Transaction 2Perrigo Confident Its Shareholders Will Reject Mylan's Value Destructive Transaction 3Perrigo Confident Its Shareholders Will Reject Mylan's Value Destructive Transaction 4Perrigo Confident Its Shareholders Will Reject Mylan's Value Destructive Transaction 5Mylan Shareholders Overwhelmingly Approve Proposed Acquisition of Perrigo 2Mylan Shareholders Overwhelmingly Approve Proposed Acquisition of Perrigo 3Mylan Shareholders Overwhelmingly Approve Proposed Acquisition of Perrigo 4Mylan Shareholders Overwhelmingly Approve Proposed Acquisition of Perrigo 5Mylan Shareholders Overwhelmingly Approve Proposed Acquisition of Perrigo 6Mylan Shareholders Overwhelmingly Approve Proposed Acquisition of Perrigo 7Mylan Shareholders Overwhelmingly Approve Proposed Acquisition of Perrigo 8Mylan Shareholders Overwhelmingly Approve Proposed Acquisition of Perrigo 9Philips presenta nuevas soluciones cardiológicas integradas para desarrollar procedimientos menos invasivos 2Philips presenta nuevas soluciones cardiológicas integradas para desarrollar procedimientos menos invasivos 3Philips presenta nuevas soluciones cardiológicas integradas para desarrollar procedimientos menos invasivos 4Philips presenta nuevas soluciones cardiológicas integradas para desarrollar procedimientos menos invasivos 5
... Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR ) ... company at the Bank of America Merrill Lynch Healthcare conference in ... Las Vegas, NV Presentation date: Tuesday May 10, 2011 ... A live webcast and 30-day archive of this presentation ...
... MELVILLE, N.Y., May 3, 2011 Henry Schein, ... healthcare products and services to office-based practitioners, today reported record ... Net sales for the first quarter of 2011 were ... quarter of 2010.  This consists of 9.9% growth in local ...
Cached Medicine Technology:Henry Schein Reports Record First Quarter Results 2Henry Schein Reports Record First Quarter Results 3Henry Schein Reports Record First Quarter Results 4Henry Schein Reports Record First Quarter Results 5Henry Schein Reports Record First Quarter Results 6Henry Schein Reports Record First Quarter Results 7Henry Schein Reports Record First Quarter Results 8Henry Schein Reports Record First Quarter Results 9
(Date:8/29/2015)... AZ (PRWEB) , ... August 30, 2015 , ... ... David O’Shea to serve as the college’s Vice President of Strategic Initiatives and Information ... is eager to help the college expand its reach and impact through innovative technologies ...
(Date:8/29/2015)... ... 29, 2015 , ... "I have been a licensed physical ... specialize in manual therapy, and my invention will provide headache sufferers a solution ... muscle dysfunction throughout the body." , They developed THE RELIEVER to alleviates headaches, ...
(Date:8/29/2015)... ... August 29, 2015 , ... Brands like Toppik , ... standard shipping costs. , “Before, a threshold of $49.00 was required to qualify for ... items qualify for free standard shipping for customers regardless of the item’s selling price.” ...
(Date:8/29/2015)... ... August 29, 2015 , ... Hamstring strain ... stretching, soft tissue manipulation. Platelet rich plasma injections also have mixed results. ... improve treatment outcomes. This localized treatment seems to address the symptoms and ...
(Date:8/28/2015)... Sierra Madre, CA (PRWEB) , ... August 28, ... ... alternative solutions to wound center management, Decatur County Memorial Hospital recently transitioned management ... model of Wound Center Management for their outpatient wound center. , ...
Breaking Medicine News(10 mins):Health News:Rio Salado College Appoints New Vice President of Strategic Initiatives and Information Services 2Health News:Inventors and InventHelp Clients Develops Tension Reliever (LGI-1951) 2Health News:TheBeautyPlace.com Discounts Shipping on Select Brands 2Health News:NEW APPROACH for Treatment of Recurrent Hamstring Strains and Hamstring Tendinosis is Available for the First Time in NYC 2Health News:NEW APPROACH for Treatment of Recurrent Hamstring Strains and Hamstring Tendinosis is Available for the First Time in NYC 3Health News:Decatur County Memorial Hospital Transitions Wound Center Management To Wound Care Advantage and the Luvo Operating System 2Health News:Decatur County Memorial Hospital Transitions Wound Center Management To Wound Care Advantage and the Luvo Operating System 3Health News:Decatur County Memorial Hospital Transitions Wound Center Management To Wound Care Advantage and the Luvo Operating System 4
... MiddleBrook,Pharmaceuticals, Inc. (Nasdaq: MBRK ), a ... products, today,announced that it has entered into definitive ... of 8,750,000 shares of,its common stock at $2.40 ... purchase 3,500,000 shares of common stock at an,exercise ...
... Respectively, Over Prior Year ... Period-, EXTON, Pa., ... for its second quarter and six,months of fiscal year 2008., Second Quarter ... income, increased 14% to $19.6 million in the Company,s second,fiscal quarter ended December ...
... Matthew L. Myers ... Tobacco-Free Kids, WASHINGTON, Jan. 24 The following statement,was ... A new global survey released by the U.S. Centers ... use, and even higher,rates of exposure to secondhand smoke, among ...
... 24 Karen Ignagni, President,and CEO of ... statement on,the Institute of Medicine,s (IOM) recommendation ... the effectiveness of healthcare products and,services:, ... deserve to know not only what medical ...
... day low price philosophy helps customers save more ... compared to prescription retail price, BENTONVILLE, Ark., ... recent prescription to over-the-counter (OTC) approved,drug, Zyrtec(R) (cetirizine ... Wal-Mart will offer eight different OTC Zyrtec products, ...
... Department of,Health and Human Services (HHS) Secretary ... standards developed by the Healthcare Information,Technology Standards ... advanced three,of its "Interoperability Specifications" to help ... a Nationwide Health Information Network in,the United ...
Cached Medicine News:Health News:MiddleBrook Pharmaceuticals to Raise $21 Million Through Private Placement of Common Equity 2Health News:MiddleBrook Pharmaceuticals to Raise $21 Million Through Private Placement of Common Equity 3Health News:MiddleBrook Pharmaceuticals to Raise $21 Million Through Private Placement of Common Equity 4Health News:Kensey Nash Reports Second Quarter EPS of $0.21 and Revenue of $19.6 Million 2Health News:Kensey Nash Reports Second Quarter EPS of $0.21 and Revenue of $19.6 Million 3Health News:Kensey Nash Reports Second Quarter EPS of $0.21 and Revenue of $19.6 Million 4Health News:Kensey Nash Reports Second Quarter EPS of $0.21 and Revenue of $19.6 Million 5Health News:Kensey Nash Reports Second Quarter EPS of $0.21 and Revenue of $19.6 Million 6Health News:Kensey Nash Reports Second Quarter EPS of $0.21 and Revenue of $19.6 Million 7Health News:Kensey Nash Reports Second Quarter EPS of $0.21 and Revenue of $19.6 Million 8Health News:Kensey Nash Reports Second Quarter EPS of $0.21 and Revenue of $19.6 Million 9Health News:Kensey Nash Reports Second Quarter EPS of $0.21 and Revenue of $19.6 Million 10Health News:Kensey Nash Reports Second Quarter EPS of $0.21 and Revenue of $19.6 Million 11Health News:Kensey Nash Reports Second Quarter EPS of $0.21 and Revenue of $19.6 Million 12Health News:Kensey Nash Reports Second Quarter EPS of $0.21 and Revenue of $19.6 Million 13Health News:New CDC Global Survey Finds Tobacco Taking Massive Toll on World's Children 2Health News:New CDC Global Survey Finds Tobacco Taking Massive Toll on World's Children 3Health News:Wal-Mart Becomes One of the First to Offer Over-the-Counter Zyrtec 2Health News:Wal-Mart Becomes One of the First to Offer Over-the-Counter Zyrtec 3Health News:HHS Secretary Recognizes Products of HITSP Standards Work 2Health News:HHS Secretary Recognizes Products of HITSP Standards Work 3Health News:HHS Secretary Recognizes Products of HITSP Standards Work 4
Colloidal Gold Conjugated, Protein A - 12 OD...
Colloidal Gold Conjugated, Protein G - 12 OD...
Colloidal Gold Sol, 40 nm - 12 - 15, 1 ml, Gold Sol Nanoparticles - not boiled, not centrifuged...
Colloidal Gold Sol, 20 nm - 12 - 15 OD, 1 ml, Gold Sol Nanoparticles - not boiled, not centrifuged...
Medicine Products: